Pharmacotherapy of Depressive Disorders in Conditions of Coronavirus Disease: Pharmacoeconomic Experimental Study




coronavirus epidemic, depressive disorders, pharmacotherapy, drugs, pharmacoeconomics


Purpose of the study was to conduct comprehensive pharmacoeconomic, clinical and pharmacological, marketing, documentary, normative and legal studies of pharmacotherapy of depressive disorders during global coronavirus pandemic. Pharmacoeconomic methods of analysis, in particular ABC/VEN analysis were used to select effective and safe drugs of pharmacotherapy of depression. According to the results of the ABC cost analysis, drugs for the pharmacotherapy of depression were distributed in descending order of their cost: group A (most expensive) includes drugs whose pharmacotherapy costs were equal to 81.76% of total costs; to group B (average cost) – 14.21%, and to group C (cheapest) – 4.03%. Group A included 10 INN drugs (including Citaloprame, Olanzapine, Fluvoxamine), the cost of one dose was 4956.5 UAH, which accounted for 81.76% of the total cost of pharmacotherapy for depression. Group B included four INNs (Sertraline, Escitaloprame, Mianserine, Sulpiride), the total cost of one dose of which was 861.3 UAH (14.21%). As part of group C – four INN (Doxepine, Lithium, Fluoxetine, Amitriptyline), the cost – 244.54 UAH per dose (4.03%). According to VEN analysis, it was experimentally proven that the highest costs of pharmacotherapy of depression were 77.7% for drugs of category V (vital) and 22.3% for drugs of category E (essential). During the VEN analysis it was found that fourteen INN drugs are included in category V (Vital). Category E includes four INNs. No INNs were included into category N (Non-Essential). The obtained results made it possible to make administrative and managerial decisions in determining the pharmacotherapy of patients with depressive disorders.

Author Biography

Viktoriia Shapovalova, Lugansk State Medical University

Doctor of Pharmaceutical Sciences, Professor, Luhansk State Medical University, Ukraine

Public Organization “Association of medical and pharmaceutical law”, Ukraine


COVID-19 dashboard by the Centre for Systems Science and Engineering at John Hopkins University. COVID-19 dashboard by the Centre for Systems Science and Engineering at John Hopkins University. 2021. URL:

Dr Fauci on Delta variant: Unvaccinated Americans risk new Covid surge. ВВС. 2021. URL:

Shapovalova V. Interdisciplinary pharmacoeconomic research concerning the pharmacotherapy of Аlcoholic Hepatitis in conditions of COVID-19 pandemic. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.2. P.1-10. URL: DOI:

Shapovalova V. Forensic and pharmaceutical risks in the organization of pharmacotherapy of covid, post-covid and long-covid disorders. COVID-19 and vaccination practice standards. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 4. P. 1–24. URL: DOI:

Shapovalova V. An Innovative multidisciplinary study of the availability of coronavirus vaccines in the world. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.2. P.1–17 URL: DOI:

Implications of the COVID-19 pandemic for patient safety: a rapid review. WHO. 05.08. 2022. URL:

Shapovalov V. Multidisciplinary study of medical errors in the system of legal relations between "Doctor-Patient-Pharmacist-Advocate" during the circulation of drugs. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.2. P.1-11. URL: DOI:

Hagezom H.M., Gebrehiwet A.B., Goytom M.H., Alemseged E.A. Prevalence of depression and associated factors among quarantined individuals during the COVID-19 pandemic in Tigrai. Treatment and quarantine centers, Tigrai, Ethiopia, 2020: A Cross-Sectional Study. Dovepress. 2021. No.14. P.2113-2119. URL: DOI:

Shapovalov V. Falsified Alcohol: Multidisciplinary Forensic and Pharmaceutical, Criminal and Legal, Clinical and Pharmacological Study of Circulation and Factors of Destruction of Human Body. SSP Modern Law and Practice. 2023. Vol.3. No.2. P.1-18. URL: DOI:

Gudzenko A. A., Shapovalov V. (Jr.) V., Shapovalova V.А. et al. Organizational and legal, forensic and pharmaceutical researches of pharmaceutical provision for mental disorders of victims in the emergencies at regional level. Likars’ka Sprava. 2018. Vol. 7-8. P. 149-157. URL: DOI:

Depression. WHO. 2018. URL:

Global health. UnFoundation. 26.03.2023. URL:

Implications of the COVID-19 pandemic for patient safety: a rapid review. WHO. 05.08. 2022. URL:

Ministry of healthcare of Ukraine official site. URL:

Health Care for All: A Framework for Moving to a Primary Care-Based Health Care System in the United States. AAFP. 19.10.2021. URL:

FDA Approves first treatment for COVID-19. FDA. 22.10.2020. URL: DOI:

Health and social responses to drug problems: a European guide. EMCDDA. October 2021. URL:

Hayduchok I. Pharmacotherapy of systemic vasculitis combined with cryoglobulinemic syndrome using pharmacoeconomic approaches. Global Journal of Health Science. 2021. Vol.13. No.7. P.78-88. DOI: 10.5539/gjhs.v13n7p78. URL: DOI:

Mamarde A. ABC/VEN Analysis of drug store in Tertiary care hospital for year 2013-2014. American Journal of Pharmaceutical Research. 2016. Vol.6. No.8. P.6439-6444.

Management Science for Health. Managing Medicines Selection. Managing Access to Medicines and Health Technologies. Arlington, VA, USA: MSH; 2012: 16.1-16.15.URL:

Snow John. United States Agency for International Development. Logistics Indicators Assessment Tool. Arlington, VA: DELIVER; 2005. URL:

Shapovalova V.O., Shekera O.G., Shapovalov V.V. et al. Control regime of drugs for pharmacotherapy of depression in combatants. An information letter about innovations Ukrmedpatentinform of the Ministry of Health of Ukraine. Kyiv: Ukrmedpatentinform of the Ministry of Health of Ukraine; 2018: 282 – 2018. 8 p.

ATC-classification. Compendium on-line. 2020. URL:

State Register of Medicines of Ukraine. URL:

On approval of the twelfth issue of the State formulary of medicines and ensuring its availability. Order of the Ministry of Health of Ukraine. Dated 06.05.2020; 1075. URL:

Brooks S., Webster R., Smith L., et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020. Vol.395. No.10227. P.912–920. URL: DOI:

Shapovalova V. Alcoholic Hepatitis: An experimental meta-analysis. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.1. P.1-11. DOI: DOI:

Islam S., Tasnim R., Sujan S. Depressive symptoms associated with COVID-19 preventive practice measures, daily activities in home quarantine and suicidal behaviors: Findings from a large-scale online survey in Bangladesh. BMC Psychiatry. 2021. Vol.21. No.1. P.273. DOI: 10.1186/s12888-021-03246-7. URL: DOI:

LaPreze J., Robinson A. The impact of COVID-19 on mental health in patients. US Pharm. 2021. Vol.46. No.6. P. 25-29. URL:

Medvedev V. E. Anxiety and depression in COVID-19: treatment options. Neurology, Neuropsychiatry, Psychosomatics. 2021. Vol.13. No.2. P.111-116. URL: DOI:

World Health Organization. Weekly epidemiological update on COVID-19. 2021. URL:

On approval and implementation of medical and technological documents for the standardization of medical care for depression. Order of the Ministry of Health of Ukraine. Dated 25.12.2014; 1003.

National list of basic medicines. Resolution of the Cabinet of Ministers of Ukraine. Dated 25.03.2009; 333.

Pharmacological treatment of depression. EBM Guidelines. 2017. URL:

Gudzenko A., Shapovalov (Jr.) V., Shapovalova V., Shapovalov V. Organization, and legal aspects of the use of marketing analysis of multivitamin complexes for pharmaceutical provision of health diseases among combatants. Acta scientific pharmaceutical sciences. 2021. Vol.5. Iss.4. P.74-80. URL: DOI:

Shapovalov V. (Jr.), Gudzenko A., Shapovalova V. et al. Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines. Pharmacia. 2017. Vol. 65. No. 2. Р. 23-29. URL:

Shapovalov V. (Jr.), Gudzenko A., Shapovalova V. et al. Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents. Pharmacia. 2017. Vol.66. Nо.3. Р. 31-39. URL:




How to Cite

Shapovalova, V. (2023). Pharmacotherapy of Depressive Disorders in Conditions of Coronavirus Disease: Pharmacoeconomic Experimental Study. SSP Modern Pharmacy and Medicine, 3(3), 1–11.



Health Sciences. Pharmacy